Novavax, Inc. has raised its adjusted revenue outlook for 2026, anticipating that milestone payments from vaccine supply and licensing agreements will counter the impact of declining demand. The biotechnology company now expects 2026 adjusted revenue to range between $230 million and $270 million, up from its previous estimate of $185 million to $205 million. This updated forecast excludes potential sales and royalties from its strategic partnership with SANOFI SA - NV26.
In its fourth-quarter financial results, the company reported a net income of $18 million, swinging from a net loss of $81 million in the prior year. Total revenue for the quarter rose 67% to $147 million, surpassing the average analyst estimate of $78.84 million. These gains were driven by significant cost-cutting measures and revenue from licensing deals.












